The study aims to:~Determine the safety and tolerability of psilocybin when administered to patients with chronic SUNHA~Determine the effects of psilocybin on cognition when administered to patients with chronic SUNHA~Explore the change in frequency, duration, and intensity of headache attacks with escalating doses of psilocybin in patients with chronic SUNHA
This exploratory open-label phase 1b, ascending dose study is to evaluate the effects of psilocybin on cognition in patients with Chronic Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)